title: Safety and efficacy of mizoribine treatment in nephrotic syndrome complicated with hepatitis B virus infection: a clinical study.
abstract: Objective The objective of this study is to explore the efficacy and safety of mizoribine (MZR) in treating nephrotic syndrome patients afflicted with hepatitis B virus (HBV). Methods The present study included 36 nephrotic syndrome patients accompanied with HBV infection. A draft of MZR (150-200 mg/d), methylprednisolone (0.6-0.8 mg/kg·d), and entecavir (0.5 mg/d) was administered to study patients over 24 weeks. The serum albumin (AlB), 24-h urine protein (24-U-TP), liver and renal functions, and HBV-DNA were quantified before and at 2, 4, 8, 12, 16, 20, and 24 weeks after the treatment. The adverse responses were recorded. Results The AlB levels of patients increased gradually after comprehensive treatment, while the 24-U-TP, serum cholesterol, and triglyceride (TG) levels declined gradually. The changes at 24 weeks post-treatment were statistically significant. Compared with the levels before treatment, the HBV-DNA, transaminase, and renal functions of the patients were not significantly altered after the treatment. No evident adverse response was found. Conclusion Treatment using MZR in combination with methylprednisolone and entecavir in HBV-positive nephrotic syndrome patients displays significant efficacy with a low incidence of adverse reactions.
authors.affiliation: a Division of Nephrology , The Third Xiangya Hospital, Central South University , Changsha , China.
authors.forename: Jishi
authors.initials: J
authors.lastname: Liu
authors.affiliation: a Division of Nephrology , The Third Xiangya Hospital, Central South University , Changsha , China.
authors.forename: Ke
authors.initials: K
authors.lastname: Zhang
authors.affiliation: a Division of Nephrology , The Third Xiangya Hospital, Central South University , Changsha , China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Ji
authors.affiliation: a Division of Nephrology , The Third Xiangya Hospital, Central South University , Changsha , China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.affiliation: a Division of Nephrology , The Third Xiangya Hospital, Central South University , Changsha , China.
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.affiliation: a Division of Nephrology , The Third Xiangya Hospital, Central South University , Changsha , China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Yong
authors.affiliation: a Division of Nephrology , The Third Xiangya Hospital, Central South University , Changsha , China.
authors.forename: Jianwen
authors.initials: J
authors.lastname: Wang
authors.affiliation: a Division of Nephrology , The Third Xiangya Hospital, Central South University , Changsha , China.
authors.forename: Jian
authors.initials: J
authors.lastname: Sun
authors.affiliation: a Division of Nephrology , The Third Xiangya Hospital, Central South University , Changsha , China.
authors.forename: Hao
authors.initials: H
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D016903:Drug Monitoring / Q000379:methods; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006147:Guanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D019694:Hepatitis B, Chronic / Q000150:complications / Q000175:diagnosis; D006801:Humans; D007677:Kidney Function Tests / Q000379:methods; D008111:Liver Function Tests / Q000379:methods; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D012263:Ribonucleosides / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D012263:Ribonucleosides; C010052:mizoribine; C413685:entecavir; D006147:Guanine
keywords: Hepatitis B virus infection; mizoribine; nephrotic syndrome; safety and efficacy